MedTrace Logo

Diabetic Macular Edema (DME) Treatment With Ranibizumab and Dexamethasone or Ranibizumab Only.

NCT04601675 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-10-26

No results posted yet for this study

Summary

The aim of this study is to evaluate the visual outcome and prognostic factors after intraocular injections of Ranibizumab or combination of Ranibizumab And Dexamethasone under pro re nata treatment regimen for Diabetic Macular Edema patients.

Conditions

  • Macular Edema

Interventions

DRUG

Ranibizumab Ophthalmic and Intravitreal Dexamethasone

Pro re nata patients with macula edema due to diabetes will receive Ranibizumab. Group A will continue to receive Ranibizumab depending on their clinical status of macular edema

DRUG

Ranibizumab Ophthalmic only

Group B will initially receive intravitreal Dexamethasone and Ranibizumab and then depending on their clinical status of macular edema, Ranibizumab will be injected.

Sponsors & Collaborators

  • He Eye Hospital

    lead OTHER

Principal Investigators

  • Wei He, M.D., Ph.D. · He Eye Specialist Hospital, Shenyang.

  • Jun Li, M.D., Ph.D. · He Eye Specialist Hospital, Shenyang.

  • Emmanuel E Pazo, M.D., Ph.D. · He Eye Specialist Hospital, Shenyang.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-31
Primary Completion
2021-03-01
Completion
2021-09-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04601675 on ClinicalTrials.gov